World Health Organization Releases Guidelines for GLP-1 Inhibitors

The World Health Organization (WHO) Guidelines on GLP-1 Inhibitors: What You Need to Know

===========================================================================================

The World Health Organization (WHO) just passed their guidelines concerning GLP-1 inhibitors (i.e., Ozempic, Mounjaro, Wegovy, and Zepbound). What does this mean for you and obesity rates? Originally formulated to treat type II diabetes, GLP-1 inhibitors gained immense popularity a few years ago. Increasing numbers of Hollywood celebrities touted these drugs as the secret to losing weight and maintaining it. Since then, demand for GLP-1 inhibitors has surged among the general public, sparking debates about their safety and potential long-term effects.

Watch the video to learn more about the WHO's new guidelines for GLP-1 drugs.

Understanding GLP-1 Inhibitors

-------------------------------

Contrary to popular belief, GLP-1 inhibitors are not a magic solution. You still need to eat healthily and exercise consistently to achieve real and sustained weight loss. With obesity rates rising in the United States and globally, it is crucial for individuals to take action in managing their weight. This is especially important as obesity-related deaths are on the rise. Let’s take a closer look at what the WHO says.

Use and Indications

According to the WHO, obesity is a chronic disease with a high potential for relapse. It requires lifelong care. They suggest that weight gain is easier to manage when action is taken early. Waiting until one is obese or morbidly obese may mean that GLP-1 inhibitors are not even necessary. Additionally, behavioral treatments, along with medical and surgical interventions, can also help individuals regain control over their weight.

The prescribed treatment for obesity varies from person to person. Some individuals may successfully lose weight with just a GLP-1 inhibitor, while others may need additional support, such as behavior therapy alongside the medication.

GLP-1 inhibitors assist with weight loss by managing hunger. These medications extend feelings of fullness and help individuals feel satisfied sooner, which reduces the likelihood of overeating. Weight gain occurs when a person consumes more calories than they burn over time. By controlling hunger and overeating, these medications can enhance weight management and success for those who struggle with eating habits.

Challenges

Treating individuals with GLP-1 inhibitors presents challenges. As Shannon Sharpe, a sports commentator and Hall of Fame tight end, once said, “The most important ability is availability.” The WHO emphasizes that to effectively combat obesity with drugs like Ozempic and Wegovy, there must be enough supply for the larger population to access these medications.

In addition to availability, the WHO stresses that GLP-1 inhibitors must be affordable. When Ozempic first gained popularity, it cost about $1,000 a month for four weekly injections. Since then, manufacturers have collaborated with insurance companies to make these products more affordable. Recently, President Trump proposed that companies continue to work on making these drugs accessible to combat obesity in the U.S.

The WHO mentioned that semaglutide, the main active ingredient in Ozempic and Mounjaro, is expected to have its patents expire in 2026. This should allow generic brands to enter the market and lower costs, expanding access to the drug for a broader range of potential customers. A greater supply of semaglutide GLP-1 inhibitors will help manage demand and may lead to a decrease in prices.

Beyond the Medication

----------------------

The benchmark for labeling a person as “obese” is a body mass index (BMI) of 30 or above. The WHO guidelines indicate that addressing obesity before reaching this threshold, or immediately upon reaching it, can simplify the weight loss process. Since obesity arises from various factors, acting sooner to manage weight makes it easier to break unhealthy habits.

However, GLP-1 inhibitors are not a magic bullet that will cause fat to melt away without any effort on your part. The WHO and most weight loss specialists agree that increasing physical activity through exercise is a beneficial lifestyle change for those looking to lose weight while using drugs like Ozempic, Wegovy, and Zepbound. Incorporating a weight training program can accelerate fat loss while supporting muscle maintenance or growth. Additionally, resistance training improves bone strength, which is crucial for individuals over 30, especially pre- and post-menopausal women.

For long-term weight loss success, the WHO guidelines on GLP-1 inhibitors encourage establishing an ecosystem that includes community building, education, and therapy support alongside widespread access to the medication. A strong relationship between pharmacological innovation and holistic therapy is essential. Criticizing or mocking someone for taking a GLP-1 inhibitor does not help.

The Future of Obesity Management

Globally, over 1 billion people are obese, and the WHO predicts this number could surpass 2 billion by 2030. In the U.S., about 40% of adults are classified as obese, with men and women aged 40-59 leading among age groups. While President Trump opted to withdraw from the WHO, his administration has taken steps to make GLP-1 inhibitors more affordable and accessible to the public. Recently, a deal was established with Eli Lilly to potentially reduce the cost of Zepbound and Mounjaro to less than $200 a month.

While the long-term impact of GLP-1 inhibitors on global obesity remains to be seen, early data suggests they may significantly lower obesity rates. Until then, whether you are taking Ozempic or another medication, it is crucial to maintain a healthy diet and exercise regularly.

About the Author

Julio Lopez is a Navy Veteran, former collegiate athlete, and personal trainer with a Master’s degree in Nutrition. He is the founder of 365 Physique Personal Training and Nutrition, where he specializes in helping busy individuals build a healthy lifestyle into their schedules. You can find Julio training his in-person clients at Versatile Fitness in east El Paso, Texas, and sharing practical tips on social media.

Want a plan that actually fits your life?

Click here to schedule your free consultation.